Valneva retransmettra aujourd’hui en direct la conférence téléphonique sur ses résultats financiers du premier trimestre 2025 à 15h00 CEST (9h00 EDT). Cette retransmission sera disponible sur le site ...

Within R&D, Novo Nordisk completed the REDEFINE 2 trial, where CagriSema demonstrated superior weight loss of 15.7% in adults with obesity or overweight and type 2 diabetes. Novo Nordisk still expects ...

Dr. Falk Pharma, a research-based pharmaceutical company specializing in digestive and metabolic medicine, today announced positive results from its pivotal, phase 3 trial (NUC-5) on norucholic acid ...

Improved disease staging tool for hepatic encephalopathy, approved for use by FDA in phase 3 trials of IV ammonia scavenger (YAQ006) Dose-response data of oral ammonia scavenger (YAQ007) for ...

CROSSJECT and its EUROFINS CDMO partner successfully completed the aseptic filling of all ZEPIZURE® registration batches and anticipate the delivery of the last manufacturing data needed for U.S. Food ...

“These data show that the long-term efficacy, safety, and convenience profile of ALXN1840 are very encouraging and that ALXN1840 has the potential to provide a meaningful benefit to Wilson disease ...

While analyzing the customer reviews of PrimeBiome, we primarily focused on whether customers have any major complaints ...

Randomised trial, 20-week treatment protocol plus 6-month follow up ...

The webcast of the fireside chats will be accessible in the investor section of 89bio’s website. A replay of the webcasts will be available for approximately 30 days following each conference.

The grants described in this press release were approved by the Compensation Committee of the Amwell’s Board of Directors pursuant to the Amwell’s Inducement Plan and made in reliance on the ...

The inducement grant consisted of time-based restricted stock units (“RSUs”) for 69,600 shares of Intellia’s common stock, with one-third of such RSUs vesting on May 1, 2026, 2027 and 2028.

IRVINE, Calif., May 06, 2025 (GLOBE NEWSWIRE) -- Beta Bionics, Inc. (Nasdaq: BBNX), a pioneering leader in the development of advanced diabetes management solutions, today reported its financial ...